{
  "docId": "019dd923-622c-750b-8b9b-7e7228555e88",
  "docSlug": "36c903ba19aa",
  "documentTitle": "Allergan, Inc. (AGN)",
  "authorId": "01_Pershing_Square",
  "authorName": "William Ackman",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2014-04-22 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.70665085,
  "pageNumber": 25,
  "pageCount": 110,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 3,
  "notes": null,
  "elementsJson": [
    "headline_text",
    "callout_box",
    "pie_chart",
    "footnote"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9b-7e7228555e88/25",
  "deckHref": "/decks/019dd923-622c-750b-8b9b-7e7228555e88",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9b-7e7228555e88.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-7e7228555e88#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.3,
        "x": 0.58,
        "y": 0.24
      },
      "kind": "callout",
      "text": "The top 10 products of Merck and Pfizer represent ~50% of revenues",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f23c1dad-e402-42da-923b-7d75879a9bc7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.35,
        "x": 0.14,
        "y": 0.22
      },
      "kind": "chart",
      "text": "Revenue Contribution by Products 2014E",
      "attrs": null,
      "subkind": "pie",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd9f46bf-38c7-4630-b977-b714431104c4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "revenue concentration: 18%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-f5d3-71df-9941-cc191c7dec18",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.8,
        "x": 0.1,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "Unlike most traditional pharmaceutical companies, Valeant has a highly diversified product portfolio minimizing product concentration risk",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b798e78-3cd3-4f41-9388-f145453e8c9d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.4,
        "x": 0.09,
        "y": 0.51
      },
      "kind": "source-note",
      "text": "Source: Company presentation January 14, 2014 at JPMorgan Conference",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "69d6b90b-7d44-46a3-a6d5-04600e59a2ee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.75,
        "x": 0.09,
        "y": 0.09
      },
      "kind": "title",
      "text": "Valeant has Low Product Concentration Risk",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f643ced3-3ef6-441f-af5d-195e9747dd5b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "8b3f97ef-8fab-4d90-b650-d4d20896446c",
      "evidence": "Although not explicitly a 2x2 matrix, the pie chart could imply a comparison.",
      "confidence": 0.5
    }
  ],
  "frameworks": [
    {
      "name": "comparison-frame",
      "slug": null,
      "matchId": "c657da21-117c-4283-8835-1fe516cae5dd",
      "evidence": "Compares Valeant's portfolio concentration against Merck and Pfizer",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}